(BUSINESS WIRE)–Helicos BioSciences Corporation (NASDAQ: HLCS – News), a life science company focused on innovative genetic analysis technologies, today announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.
Market Club has a very interesting take on how HLCS is playing out after the past volume surge. The “Trade Triangles” paint the picture. CLICK HERE and just enter the ticker (HLCS) your name and e-mail address for the FREE No strings Attached Report sent realtime to your in-box!
“We are very excited to be working with such a distinguished institution on the application of our technology to the study of cancer genomics” stated Ron Lowy, Helicos Chief Executive Officer.
The Helicos Genetic Analysis System is the world’s first and only commercially available, single molecule sequencing technology, and enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos’s technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.
